Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Bristol-Myers Squibb Company scopre, sviluppa, concede in licenza, produce, commercializza, distribuisce e vende prodotti biofarmaceutici in tutto il mondo. L'azienda offre prodotti per indicazioni oncologiche, ematologiche, immunologiche, cardiovascolari e neuroscientifiche.
Tradotto automaticamente
Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →
| Conto economico | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrate totali | $49.2B | $48.2B | $48.3B | $45.0B | $46.2B | $46.4B | $42.5B | $26.1B | $22.6B | $20.8B | $19.4B | $16.6B | $15.9B | $16.4B | $17.6B | $21.2B | $19.5B | $18.8B | $20.6B | $19.3B | $17.9B |
| Utile lordo | $34.5B | $34.3B | $27.4B | $25.4B | $26.5B | $26.8B | $21.7B | $17.2B | $16.1B | $15.0B | $14.5B | $12.8B | $12.0B | $11.8B | $13.2B | $15.7B | $14.3B | $13.8B | $14.4B | $13.2B | $11.7B |
| Margine lordo% | 70.2% | 71.1% | 56.8% | 56.3% | 57.4% | 57.7% | 51.0% | 66.0% | 71.2% | 72.0% | 74.6% | 77.3% | 75.6% | 72.0% | 74.8% | 74.0% | 73.6% | 73.2% | 70.1% | 68.3% | 65.2% |
| Risultato Operativo (EBIT) | $13.9B | $13.7B | $9.7B | $8.5B | $9.3B | $9.5B | $4.5B | $6.4B | $6.4B | $5.2B | $5.2B | $3.9B | $3.1B | $3.1B | $4.3B | $6.8B | $6.1B | $5.0B | $4.9B | $3.8B | $2.6B |
| Margine operativo % | 28.3% | 28.5% | 20.0% | 18.8% | 20.1% | 20.6% | 10.6% | 24.6% | 28.3% | 25.2% | 26.7% | 23.8% | 19.7% | 19.1% | 24.2% | 31.8% | 31.5% | 26.8% | 23.7% | 19.5% | 14.8% |
| Reddito netto | $9.3B | $7.1B | ($8.9B) | $8.0B | $6.3B | $7.0B | ($9.0B) | $3.4B | $4.9B | $1.0B | $4.5B | $1.6B | $2.0B | $2.6B | $2.0B | $3.7B | $3.1B | $10.6B | $5.2B | $2.2B | $1.6B |
| Margine netto% | 18.9% | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | 15.6% | 11.1% | 17.5% | 15.9% | 56.4% | 25.5% | 11.2% | 8.8% |
| EBITDA | $16.7B | $15.2B | $3.2B | $19.4B | $19.2B | $20.1B | $4.9B | $7.4B | $6.8B | $6.1B | $6.5B | $2.6B | $3.1B | $3.9B | $3.2B | $7.8B | $6.8B | $6.5B | $5.9B | $4.4B | $3.3B |
| Utile per azione (EPS) | $4.54 | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.98 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | $1.54 | $1.16 | $2.16 | $1.80 | $5.37 | $2.62 | $1.09 | $0.81 |
| Azioni in circolazione (M) | 2,048M | 2,041M | 2,027M | 2,078M | 2,146M | 2,245M | 2,258M | 1,712M | 1,637M | 1,652M | 1,680M | 1,679M | 1,670M | 1,662M | 1,688M | 1,717M | 1,727M | 1,978M | 2,001M | 1,980M | 1,963M |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di BMY. /companies/us/BMY
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms